Arix Bioscience appoints Meghan FitzGerald to Board of Directors

 

LONDON, 21 July 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience”, or the “Company”), a global healthcare and life science company supporting medical innovation, today announces the appointment of Meghan FitzGerald as a Non-Executive Director of the Company. The appointment is with immediate effect and she will be a member of the Board’s Audit Committee.

 

Meghan FitzGerald is a Partner of L1 Health, with a focus on investing in healthcare services. She is also an Associate Professor of Strategy and Health Policy at Columbia University.

 

Prior to L1 Health, Meghan served as Executive Vice President of Strategy and Health Policy at Cardinal Health, the global integrated healthcare services and products provider. She previously served as the President of Cardinal’s Specialty Solutions division. Meghan holds a DrPh in Healthcare Policy from New York Medical College, a BSN in Nursing from Fairfield University, and a Master of Public Health from Columbia University.

 

"Meghan brings broad experience in the US healthcare industry, with a strong emphasis on operations, health policy and business development. I am very pleased to announce her appointment, and look forward to working with her."

Jonathan Peacock

Chairman of Arix Bioscience

“I am delighted to join the Board of Arix Bioscience, with its world-class team and growing portfolio of innovative young businesses. I look forward to working with the Board and supporting the executive team to nurture important new therapies for patients and realise substantial value for shareholders.”

Dr. Meghan FitzGerald

For more information, please contact:

 

Arix Bioscience plc

Joe Anderson, CEO

+44 (0) 20 7290 1052

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

 

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com


Back to previous page